The reporting of methods for reducing and detecting bias: An example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial

BMC Medical Research Methodology

Volumn 3, Issue , 2003, Pages 1-7

  Piaggio, Gilda ^a   Elbourne, Diana ^b   Schulz, Kenneth F ^c   Villar, José ^a   Pinol, Alain P Y ^a   Gülmezoglu, A Metin ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; OXYTOCIN;

ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG PACKAGING; DRUG SCREENING; LABOR; MATERNITY WARD; METHODOLOGY; RISK REDUCTION; SENSITIVITY ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 3042628543     PISSN: 14712288     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2288-3-19     Document Type: Article

References (22)

1. Schulz KF, Chalmers I, Hayes RJ and Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412.
2. Schulz KF and Grimes DA: Allocation concealment in randomised trials: defending against deciphering. Lancet 2002, 359:614-618.
3. Schulz KF: Randomised trials, human nature, and reporting guidelines. Lancet 1996, 348:596-598.
4. CONSORT Group: Improving the quality of reporting of randomised controlled trials: the CONSORT statement. JAMA 1996, 276:637-639.
5. Moher D, Schulz KF and Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357:1191-1194.
6. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC and Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694.
7. Gülmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, Abdel-Aleem H, Cheng L, Hofmeyr G, Lumbiganon P, Unger C, Prendiville W, Pinol A, Elbourne D, El Refaey H and Schulz K: WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001, 358:689-695.
8. El Refaey H, O'Brien P, Morafa W, Walder J and Rodeck C: Misoprostol for third stage of labour. Lancet 1996, 347:1257.
9. El Refaey H, O'Brien P, Morafa W, Walder J and Rodeck C: Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol 1997, 104:336-339.
10. Gülmezoglu AM and Forna F: Prostaglandins for prevention of postpartum haemorrhage. The Cochrane Library 3. Oxford: Update Software. Ref Type: Electronic Citation 2001.
11. Hofmeyr GJ, Nikodem VC, de Jager M and Drakely A: Side-effects of oral misoprostol in the third stage of labour: a randomised placebo controlled trial. S Afr Med J 2001, 91:432-435.
12. Lumbiganon P, Hofmeyr J, Gülmezoglu AM, Pinol A and Villar J: Misoprostol dose-related shivering and pyrexia in the third stage of labour: WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour. Br J Obstet Gynaecol 1999, 106:304-308.
13. El Refaey H: Use of misoprostol in third stage of labour. Lancet 2002, 359:707-708.
14. Khan R and Sharma S: Use of misoprostol in third stage of labour. Lancet 2002, 359:708-709.
15. O'Brien P, Lokugamage AU, Guillebaud J and Rodeck CH: Use of misoprostol in third stage of labour. Lancet 2002, 359:708-710.
16. Shannon C and Winikoff B: Use of misoprostol in third stage of labour. Lancet 2002, 359:709-710.
17. Villar J, Gulmezoglu AM, Hofmeyr GJ, Cheng L and Elbourne D: Use of misoprostol in third stage of labour. Lancet 2002, 359:709-710.
18. Schulz KF and Grimes DA: Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002, 359:515-519.
19. Schulz KF and Grimes DA: Unequal group sizes in randomised trials: guarding against guessing. Lancet 2002, 359:966-970.
20. Schulz KF, Chalmers I and Altman DG: The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002, 136:254-259.
21. Schulz KF and Grimes DA: Blinding in randomised trials: hiding who got what. Lancet 2002, 359:696-700.
22. McAlister FA and Sackett DL: Active-control equivalence trials and antihypertensive agents. Am J Med 2001, 111:553-558.